Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GMNN | O75496 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | SHBG | P04278 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ANPEP | P15144 | 2/20 | 0.35 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22490222 | 1.00 | TP53 (0.46) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL892741 | 1.00 | TP53 (0.46) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL15129290 | 1.00 | TP53 (0.46) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL11651517 | 1.00 | TP53 (0.46) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL11645930 | 1.00 | TP53 (0.46) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL15129510 | 1.00 | TP53 (0.46) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL19228684 | 1.00 | TP53 (0.46) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL133226 | 1.00 | TP53 (0.46) | TP53KDM4EGMNNLMNAMAPT | |
| Hydrochloric Acid SCHEMBL14935389 | 0.97 | KDM4E (0.48) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL1439631 | 0.97 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12195446-B2 | Heteroaryl compounds and their use as therapeutic drugs | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-01-14 | — | — | US | disclosed |
| CN-113493450-B | Ligand compound, preparation method thereof and application thereof in asymmetric reaction | 中国科学院福建物质结构研究所 | 2023-07-25 | — | — | CN | disclosed |
| US-20230002353-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2023-01-05 | — | — | US | disclosed |
| US-20220177508-A1 | C10-Cyclic Substituted 13-Membered Macrolides and Uses Thereof | ZIKANI THERAPEUTICS, INC. | 2022-06-09 | — | — | US | disclosed |
| CN-108368083-B | Heteroaryl compounds and their use as therapeutic agents | 东亚首希控股股份有限公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-107207476-B | Indole and azaindole derivatives and their use in neurodegenerative diseases | 默克专利有限公司 | 2021-03-19 | — | — | CN | disclosed |
| US-10947215-B2 | Heteroaryl compounds and their use as therapeutic drugs | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2021-03-16 | — | — | US | disclosed |
| US-10676433-B2 | Indole derivatives and their use in neurodegenerative diseases | MERCK PATENT GMBH (DE) | 2020-06-09 | — | — | US | disclosed |
| EP-3344613-B1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2020-03-04 | — | — | EP | disclosed |
| US-10323000-B2 | Indole derivatives and their use in neurodegenerative diseases | MERCK PATENT GMBH (DE) | 2019-06-18 | — | — | US | disclosed |
| US-7553861-B2 | Dipeptidyl peptidase-IV inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-7326786-B2 | Thiazolinone unsubstituted quinolines | HOFFMANN-LA ROCHE INC. (US) | 2008-02-05 | — | — | US | disclosed |
| CN-1984909-A | Thiazolinone unsubstituted quinolines | HOFFMANN LA ROCHE (CH) | 2007-06-20 | — | — | CN | disclosed |
| WO-2006116157-A9 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | ALANTOS PHARMACEUTICALS INC (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20060004045-A1 | Thiazolinone unsubstituted quinolines | CHEN LI | 2006-01-05 | — | — | US | disclosed |
| EP-0813533-A4 | SUBSTITUTED N-CYCLOALKYLMETHYL-1H-PYRAZOLO 3,4-b]QUINOLIN-4 AMINES AND COMPOSITIONS AND METHODS OF USE THEREOF | SANOFI WINTHROP INC (US) | 2000-01-19 | — | — | EP | disclosed |
| US-5942520-A | Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines | CELL PATHWAYS, INC. (US) | 1999-08-24 | — | — | US | disclosed |
| EP-0813533-A1 | SUBSTITUTED N-CYCLOALKYLMETHYL-1H-PYRAZOLO 3,4-b]QUINOLIN-4 AMINES AND COMPOSITIONS AND METHODS OF USE THEREOF | SANOFI WINTHROP, INC. (US) | 1997-12-29 | — | — | EP | disclosed |
| WO-1996028446-A1 | SUBSTITUTED N-CYCLOALKYLMETHYL-1H-PYRAZOLO[3,4-b]QUINOLIN-4 AMINES AND COMPOSITIONS AND METHODS OF USE THEREOF | SANOFI WINTHROP, INC. (US) | 1996-09-19 | — | — | WO | disclosed |
| US-5488055-A | ADMINISTERING GMP HOSPHODIESTERASE INHIBITORS FOR TREATMENT OF CONGESTIVE HEART FAILURE AND CARDIOVASCULAR DISORDERS | SANOFI WINTHROP INC. (US) | 1996-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10947215-B2 | Heteroaryl compounds and their use as therapeutic drugs | MERTK, ERBB2, SRC | TP53 304/4885KDM4E 1727/4885GMNN 4372/4885 |
| US-12195446-B2 | Heteroaryl compounds and their use as therapeutic drugs | MERTK, ERBB2, SRC | TP53 304/4885KDM4E 1727/4885GMNN 4372/4885 |
| US-10323000-B2 | Indole derivatives and their use in neurodegenerative diseases | P2RX3, ADORA2A, P2RX7 | TP53 2360/4885KDM4E 2136/4885GMNN 4294/4885 |
| US-20230002353-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | MERTK, ERBB2, SRC | TP53 304/4885KDM4E 1727/4885GMNN 4372/4885 |
| US-20220177508-A1 | C10-Cyclic Substituted 13-Membered Macrolides and Uses Thereof | RPS14, RPL12, RPL13A | TP53 4628/4885KDM4E 2423/4885GMNN 2047/4885 |
| US-10676433-B2 | Indole derivatives and their use in neurodegenerative diseases | P2RX3, ADORA2A, P2RX7 | TP53 2360/4885KDM4E 2136/4885GMNN 4294/4885 |
| US-20060004045-A1 | Thiazolinone unsubstituted quinolines | CDK1, CDK17, CDK14 | TP53 102/4885KDM4E 892/4885GMNN 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.